We have located links that may give you full text access.
Fusion kinases identified by genomic analyses of sporadic microsatellite instability-high colorectal cancers.
Clinical Cancer Research 2018 October 3
PURPOSE: Colorectal cancers (CRCs) with microsatellite instability-high (MSI-H) status, due to mismatch repair deficiency, are associated with poor patient outcomes after relapse. We aimed to identify novel therapeutic targets for them.
EXPERIMENTAL DESIGN: We performed MSI analyses of over 2,800 surgically resected colorectal tumors obtained from consecutive patients treated in Japan from 1998 through June 2016. Whole-exome sequencing, transcriptome sequencing, and methylation analyses were performed on 149 of 162 tumors showing MSI in BAT25 and BAT26 loci. We analyzed patient survival times using Bonferroni-adjusted log-rank tests.
RESULTS: Sporadic MSI-H CRCs with promoter methylation of MLH1 (called MM) had a clinicopathological profile that was distinct from that of CRCs of patients with germline mutations (Lynch syndrome-associated) or somatic, Lynch-like mutations in mismatch repair genes. MM tumors had more insertions and deletions and more recurrent mutations in BRAF and RNF43 than Lynch syndrome-associated or Lynch-like MSI-H tumors. Eleven fusion kinases were exclusively detected in MM MSI-H CRCs lacking oncogenic KRAS / BRAF missense mutations and were associated with worse post-relapse prognosis. We developed a simple method to identify MM tumors and applied it to a validation cohort of 28 MSI-H CRCs, identifying 16 MM tumors and 2 fusion kinases.
CONCLUSIONS: We discovered that fusion kinases are frequently observed among sporadic MM MSI-H CRCs. The new method to identify MM tumors enables us to straightforwardly group MSI-H patients into candidates of Lynch syndrome or fusion kinase carriers.
EXPERIMENTAL DESIGN: We performed MSI analyses of over 2,800 surgically resected colorectal tumors obtained from consecutive patients treated in Japan from 1998 through June 2016. Whole-exome sequencing, transcriptome sequencing, and methylation analyses were performed on 149 of 162 tumors showing MSI in BAT25 and BAT26 loci. We analyzed patient survival times using Bonferroni-adjusted log-rank tests.
RESULTS: Sporadic MSI-H CRCs with promoter methylation of MLH1 (called MM) had a clinicopathological profile that was distinct from that of CRCs of patients with germline mutations (Lynch syndrome-associated) or somatic, Lynch-like mutations in mismatch repair genes. MM tumors had more insertions and deletions and more recurrent mutations in BRAF and RNF43 than Lynch syndrome-associated or Lynch-like MSI-H tumors. Eleven fusion kinases were exclusively detected in MM MSI-H CRCs lacking oncogenic KRAS / BRAF missense mutations and were associated with worse post-relapse prognosis. We developed a simple method to identify MM tumors and applied it to a validation cohort of 28 MSI-H CRCs, identifying 16 MM tumors and 2 fusion kinases.
CONCLUSIONS: We discovered that fusion kinases are frequently observed among sporadic MM MSI-H CRCs. The new method to identify MM tumors enables us to straightforwardly group MSI-H patients into candidates of Lynch syndrome or fusion kinase carriers.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association.Circulation 2024 April 19
Essential thrombocythaemia: A contemporary approach with new drugs on the horizon.British Journal of Haematology 2024 April 9
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app